Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database
|
|
- Rosanna Porter
- 6 years ago
- Views:
Transcription
1 doi: /j x Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database H-C Diener 1, DW Dodick 2, PJ Goadsby 3, RB Lipton 4, M Almas 5 & B Parsons 5 1 Department of Neurology, University of Duisburg-Essen, Essen, Germany, 2 Department of Neurology, Mayo Clinic, Scottsdale, AZ, USA, 3 Headache Group, Institute of Neurology, London, UK, 4 Department of Neurology, Albert Einstein College of Medicine and 5 Pfizer Global Pharmaceuticals, New York, NY, USA Diener H-C, Dodick DW, Goadsby PJ, Lipton RB, Almas M & Parsons B. Eletriptan in migraine: identification of negative predictors of pain-free response. Cephalalgia 2008; 28: London. ISSN Thirty to forty percent of migraineurs do not respond to any given triptan treatment. We identified clinical variables that significantly predict therapeutic non-response and evaluated the efficacy of eletriptan (20, 40 and 80 mg) and sumatriptan (100 mg) vs. placebo in a subgroup of patients with all predictor variables. First-attack data were pooled from 10 randomized, double-blind, placebo-controlled migraine trials (n = 8473). Multivariate regression analyses identified three significant baseline predictors of failure to achieve 2-h pain-free response: severe headache pain, presence of photophobia/phonophobia and presence of nausea. Time of dosing following headache onset did not influence 2-h pain-free response. Among patients with all three risk factors (n = 2010; 24% of total sample), 2-h pain-free response was significantly higher in patients receiving all three doses of eletriptan or sumatriptan vs. placebo (all P < 0.01). Thus, eletriptan and sumatriptan are efficacious in difficult-to-treat patients at high risk for non-response to triptans. Eletriptan, migraine, risk factors, sumatriptan, triptans Professor Dr Hans-Christoph Diener, Department of Neurology, University of Duisburg-Essen, Hufelandstr. 55, Essen, Germany. Tel /61, fax , h.diener@uni-essen.de Received 24 March 2007, accepted 19 July 2007 Introduction In clinical practice, previous treatment response is a useful way of categorizing migraine patients who present for evaluation. Treatment response histories range from patients with new-onset migraine who respond to non-specific analgesics (e.g. nonsteroidal anti-inflammatory drugs); to patients who are non-responsive to treatment with more specific acute migraine therapies such as a triptan (5-HT 1B/1D agonists) or ergotamine; to patients who are treatment refractory to trials of two or more migraine-specific therapies (1). An estimated 30 40% of patients do not respond to any given triptan they receive (2). However, this does not necessarily mean these patients are treatment refractory, and a growing body of evidence reports that within-class switching is an effective strategy for converting initial non-response to response (3 9). Individuals in this non-responder subgroup are more likely to lapse from medical care than responders (10). Furthermore, because of the reduced productivity associated with untreated migraine and the increased utilization of expensive emergency room services, it would be useful to identify patients who are at high risk of nonresponse and manage their migraine more effectively. Approaches that can be used include managing patient expectations (even if the first treatment fails, success is likely) and altering the acute treatment strategy by using a triptan that has demonstrated superior antimigraine efficacy (2, 11, 12). A previous investigation, using multivariate regression methodology on a database of 128 clinical trials (assessing migraineurs), has 35
2 36 H-C Diener et al. identified severity of baseline headache pain, functional disability and the presence of vomiting as significant predictors of failure to achieve a 2-h pain-free response on sumatriptan [overall model odds ratio (OR) 2.3, 95% confidence interval (CI) 3.3, 6.4] (13). In the current investigation the original findings of this study were replicated for headache severity. Subsequently, the presence of headache severity and other negative response predictors was used to define a high-risk treatment group, based on pooled data, regardless of treatment group. The comparative benefit of eletriptan (20, 40 and 80 mg) and sumatriptan (100 mg) vs. placebo in the subgroup of patients at high risk of failure to achieve a 2-h pain-free response is reported. Methods Data were combined from 10 double-blind, placebocontrolled, parallel-group, multicentre studies of eletriptan in the acute treatment of migraine (4, 14 22). (Note that one of the 10 studies has not been published individually.) The current analysis was performed using first-attack data for the following study treatments: eletriptan 20 mg (E20; n = 434), eletriptan 40 mg (E40; n = 3340), eletriptan 80 mg (E80; n = 1854), sumatriptan 100 mg (S100; n = 1126) and placebo (n = 1719). The combined studies had similar designs, as summarized in previous reports (4, 14 22). Briefly, adult patients were enrolled if they met the International Headache Society criteria for migraine with or without aura (23) and reported a monthly frequency of one to six attacks. Key exclusion criteria were coronary artery disease, heart failure, uncontrolled hypertension or abnormal electrocardiogram; hypersensitivity or known contraindication to treatment with eletriptan or sumatriptan; misuse or abuse of alcohol or other substances, including analgesics or ergotamine; and women who were pregnant or breast-feeding. The study protocols were approved by Institutional Review Boards (Ethics Committees) at each site, and written informed consent was obtained prior to study entry. Study procedures All studies were conducted in compliance with Good Clinical Practice guidelines (24). Data collection procedures were similar across all studies. Patients were instructed to take study medication when they experienced a typical migraine attack of moderate or severe intensity that was not spontaneously improving. Patients took study treatment when the aura phase (if present) had ended, and within 6 h of the onset of headache pain. Treatment with study medication was not permitted if the patient had used an analgesic or antiemetic during the previous 6 h, or had taken another triptan or ergotamine-containing or ergottype medication (e.g. dihydroergotamine) during the previous 24 h. In studies where patients treated more than one attack, only data from the first attack were used. Headache severity was recorded immediately prior to dosing and at a predetermined time postdose. Demographic and clinical characteristics were assessed at the screen visit. The efficacy outcome used in the current analysis was pain-free response at 2 h postdose. Statistical analyses Multivariate logistic regression (Proc Logistic; SAS Inc., Cary, NC, USA), performed on combined data from both the drug and placebo treatment groups, was used to evaluate the extent to which the following variables contributed to 2-h pain-free response rates: gender, age, aura subtype (by history), baseline severity of headache pain, baseline functional disability, baseline nausea or vomiting, baseline photophobia and/or phonophobia, number of previous migraine attacks (number of attacks in the 3 months immediately prior to study initiation) and time of dosing (time between onset of headache and treatment). Factors with P < 0.05 were selected to be included in the shorter model and factors with P > 0.05 were excluded from the model. Based on the logistic regression, a subgroup of patients at high risk of non-response was identified, as characterized by the presence of three significant predictors of not achieving 2-h pain-free response: severe baseline headache pain, photophobia and/or phonophobia, and nausea. An analysis of variance SAS procedure (GENMOD) was used to evaluate the effect of study treatment on 2-h pain-free response in the high-risk subgroup. This model included pain-free response as the outcome variable, with treatment, age and number of migraine attacks in the past 3 months as covariates. Results The combined treatment sample consisted of 8473 patients. The majority of patients (84 86%) were female and aged between 30 and 50 years, reporting two to four migraine attacks per month, typically
3 Table 1 Patient baseline demographic and clinical characteristics and characteristics of treated attack Eletriptan in migraine 37 Placebo n = 1719 S100 n = 1126 E20 n = 434 E40 n = 3340 E80 n = 1854 Patient characteristics Female, % Age, years (mean SD) Aura subtype, % Without aura With aura Mixed Attack frequency in past 3 months, mean SD Characteristics of treated attack Time from attack onset to dosing, hours, mean SD Headache pain, severe, % Incidence of associated symptoms, % Nausea Photophobia/phonophobia Functional impairment Severe or bed rest, % Response (%) Placebo (n = 1719) P < vs. placebo S100 (n = 1126) without aura (Table 1). Severe headache pain was reported in approximately 40% of patients, and approximately 84% reported attack-related impairment as severe, or resulting in bed rest. Demographic and clinical characteristics were similar for each treatment group (Table 1). For the total (pooled) sample, treatment with all three doses of eletriptan and S100 was associated with significantly higher 2-h pain-free response compared with placebo (P < ; Fig. 1). Logistic regression analysis examined the influence of individual demographic and clinical variables on 2-h pain-free response. The strongest predictors of failure to achieve a 2-h pain-free response were: severe baseline headache pain (OR E20 (n = 434) E40 (n = 3340) E80 (n = 1854) Figure 1 Pain-free response at 2 h postdose (total sample). 1.45, 95% CI 1.3, 1.6; P < ), the presence of photophobia and/or phonophobia (OR 1.37, 95% CI 1.2, 1.6; P < ) and the presence of nausea (OR 1.24, 95% CI 1.1, 1.4; P < ; Table 2). The time at which the study drug was taken in relation to headache onset had no influence on 2-h pain-free response (Fig. 2). Effect of study treatment in the high-risk subgroup A high-risk subgroup was defined based on the presence of the three variables significantly associated with inability to achieve pain-free status at 2 h postdose: the presence at baseline of severe headache pain, photophobia and/or phonophobia, and nausea. The subgroup consisted of 2010 migraineurs (24% of the total treatment sample) in the following treatment groups: E20 (n = 89), E40 (n = 760), E80 (n = 462), S100 (n = 286) and placebo (n = 413). In this high-risk subgroup, significantly higher pain-free response rates were achieved on E20 (12%; P < 0.005), E40 (22%; P < ), E80 (28%; P < ) and S100 (17%; P < ) than placebo (4%; Fig. 3; Table 3). Discussion In the current study, multivariate logistic regression, performed on the combined treatment and
4 38 H-C Diener et al. Table 2 Significant pretreatment predictors of failure to achieve pain-free status at 2 h postdose: results of logistic regression analyses (n = 8055) Estimated coefficient OR (95% CI) P-value Age (1, 1.02) Attack frequency (0.98, 1.0) Female vs. male (1.1, 1.5) 0.01 Baseline headache pain: moderate (1.3, 1.6) < vs. severe Photophobia/phonophobia: absent (1.2, 1.6) < vs. present Nausea: absent vs. present (1.1, 1.4) Response (%) Placebo (n = 1648) S100 (n = 1126) E20 (n = 434) E40 (n = 3188) E80 (n = 1126) > 4 Time of drug ingestion after headache onset (h) Figure 2 Time from headache onset to drug ingestion does not influence pain-free response at 2 h postdose. Response (%) Placebo (n = 413) P < 0.005; P < vs. placebo P < vs. S100 S100 (n = 286) placebo groups, identified three baseline clinical variables (severe baseline headache pain, photophobia and/or phonophobia, and nausea) as defining a subgroup of patients at high risk of non-response E20 (n = 89) E40 (n = 760) E80 (n = 462) Figure 3 Pain-free response at 2 h postdose: results for the high-risk subgroup. (i.e. inability to achieve 2-h pain-free response). Three other variables (female gender, older age, and lower attack frequency) were also associated with failure to achieve a 2-h pain-free response. Despite recent research suggesting that early dosing significantly improves treatment efficacy (25), the current analysis found that time of triptan administration did not influence either headache response or 2-h pain-free response. The results from these placebocontrolled trials show that baseline headache severity, and not time from onset of the attack until drug intake, more accurately predicts acute treatment outcomes. Thus, early dosing may be effective for a slowly developing migraine if treatment is initiated when headache pain is of mild-to-moderate intensity, but may not have any additional benefits over later dosing in managing attacks where the initial pain intensity is severe. This result is consistent with a previously reported study that found that time of drug administration (relative to headache onset) has less influence on treatment response than baseline pain intensity (26). The results of the current analysis found eletriptan to be efficacious in the difficult-to-treat subgroup of patients at high risk of non-response. Notable was the steep dose response curve exhibited by this high-risk subgroup: 12%, 22% and 28% of migraineurs on E20, E40 and E80, respectively, achieved 2-h pain-free response. In contrast, among triptan-naive patients (those who had never used a triptan) the dose response curve has a much more shallow slope: 20%, 28% and 31% of migraineurs on E20, E40 and E80, respectively, achieved 2-h painfree response (27). A previous multivariate analysis of the sumatriptan-controlled trial database has also identified severe baseline headache pain as the most significant negative predictor of 2-h pain-free response (13). The subgroup of patients with severe
5 Eletriptan in migraine 39 Table 3 ANOVA comparison of pain-free response at 2 h postdose: results for the group at risk of not achieving pain-free response Estimated coefficient OR (95% CI) P-value E20 vs. placebo (1.5, 10.2) <0.005 E40 vs. placebo (4.4, 13.7) < E80 vs. placebo (5.4, 17.3) < S100 vs. placebo (2.9, 10.1) < E20 vs. S (0.3, 1.7) 0.5 E40 vs. S (1.0, 2.1) 0.06 E80 vs. S (1.2, 2.7) <0.004 baseline headache pain in the sumatriptan database analysis had a 2-h pain-free response rate of 19% on S100. This is very similar to the rate of 17% on sumatriptan observed for the high-risk subgroup in the current study, even though the latter subgroup of high-risk patients had additional negative response predictors (13). These results support the findings of previous studies, confirming severe baseline pain intensity as an important negative predictor of a pain-free outcome at 2 h after the administration of a triptan. The important and pragmatic clinical implication is that patients, where possible, should be strongly encouraged to treat a migraine headache before pain intensity becomes severe to achieve optimal acute treatment outcome. Competing interests This study was supported by Pfizer Inc. M.A. and B.P. are employees of Pfizer Inc. H-C.D. has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from: Addex Pharma, Allergan, Almirall, AstraZeneca, Bayer Vital, Berlin Chemie, CoLucid, Böhringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Grünenthal, Janssen-Cilag, La Roche, 3M Medica, MSD, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi-Aventis and Weber & Weber. He has received financial support for research projects from Allergan, Almirall, AstraZeneca, Bayer, Glaxo- SmithKline, Janssen-Cilag and Pfizer. Headache research at the Department of Neurology in Essen is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union. D.W.D. is a consultant/advisor for Allergan, Eli Lilly, Endo, GlaxoSmithKline, Medtronic, Merck, Neuralieve, OrthoMcNeil and Pfizer. He has received research support from Advanced Bionics, AstraZeneca, and Medtronic, and is principal investigator of Phase IIII clinical trials with Allergan and St Jude. P.J.G. has collaborated with, advised and received support for research from Advanced Bionics, Almirall, Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, MSD, Pfizer, and Pozen. R.B.L. has consulted for, received lecture honoraria from and conducted studies funded by Advanced Bionics, Allergan Inc, Bristol-Myers Squibb, GlaxoSmithKline, Johnson & Johnson, Merck, NeuraLieve, Pfizer and ProEthics. Acknowledgements This study was supported by Pfizer Inc. The research question was conceived by H-C.D., D.W.D., P.J.G. and R.B.L. Pfizer collated the database, and ran the statistical analysis. The primary data output was analysed collectively during an expert working group that included all authors. The authors would like to acknowledge Anthony Donoghue for statistical programming support. Editorial support was provided by Edward Schweizer, MD and GCL, London, and was funded by Pfizer Inc. References 1 Pascual J. New perspectives in migraine treatment: how to treat the difficult migraine patient. Neurologia 2004; 19 (Suppl. 2): Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002; 22: Goldstein J, Tiseo PJ, Albert KS, Li C, Sykes CR. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006; 46: Färkkilä M, Olesen J, Dahlöf C, Stovner LJ, ter Bruggen JP, Rasmussen S et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003; 23:
6 40 H-C Diener et al. 5 Mathew NT, Kailasam J, Gentry P, Chernyshev O. Treatment of nonresponders to oral sumatriptan with zolmitriptan and rizatriptan: a comparative open trial. Headache 2000; 40: Stark SR, Spierings EL, McNeal S, Putnam DG, Bolden- Watson CP, O Quinn S. Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan. Headache 2000; 40: Diener HC, Gendolla A, Gebert I, Beneke M. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Eur Neurol 2005; 53 (Suppl. 1): Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache 2005; 45: Sheftell FD, Feleppa M, Tepper S, Volcy M, Rapoport AM, Bigal ME. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache 2004; 44: Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology 2002; 58: Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neurol Scand 2004; 110: Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002; 97: Diener HC, Ferrari M, Mansbach H, SNAP Database Study Group. Predicting the response to sumatriptan. Neurology 2004; 63: Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot ) in the acute treatment of migraine: a multicentre, randomised, doubleblind, placebo-controlled comparison. Eur Neurol 2002; 47: Garcia-Ramos G, MacGregor EA, Hilliard B, Bordini CA, Leston J, Hettiarachchi J. Comparative efficacy of eletriptan vs. naratriptan in the acute treatment of migraine. Cephalalgia 2003; 23: Goadsby PJ, Ferrari MD, Olesen J, Stovner LJ, Senard JM, Jackson NC et al. Eletriptan in acute migraine: a doubleblind, placebo-controlled comparison to sumatriptan. Eletriptan Steering Committee. Neurology 2000; 54: Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003; 43: Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003; 43: Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S. Eletriptan vs sumatriptan: a double-blind, placebocontrolled, multiple migraine attack study. Neurology 2002; 59: Sheftell F, Ryan R, Pitman V. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003; 43: Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR. Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003; 23: Stark SR, Dahlöf C, Haughie S, Hettiarachchi J, Eletriptan Steering Committee. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002; 22: Headache Classification Committee of the International Headache Society. Classification and diagnosis criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 (Suppl. 7): International Conference on Harmonization. Guidance for industry. E6 good clinical practice: consolidated guidance Available at guidance/959fnl.pdf Last accessed June Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123: Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR. Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005; 25: Martin V, Valade D, Almas M, Hettiarachchi J, Sikes C, Albert KS et al. Efficacy of eletriptan in triptan-naive patients: results of a combined analysis. Headache 2007; 47:181 8.
Clinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
More informationA new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results
J Headache Pain (2004) 5:S112 S116 DOI 10.1007/s10194-004-0123-4 Michele Feleppa Fred D. Sheftell Luciana Ciannella Amedeo D Alessio Giancarlo Apice Nino N. Capobianco Donato M.T. Saracino Walter Di Iorio
More informationDevelopment and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan
J Headache Pain (2008) 9:359 365 DOI 10.1007/s10194-008-0070-6 ORIGINAL Development and validation of a pharmacy migraine questionnaire to assess suitability for treatment with a triptan Hans-Christoph
More informationEletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study
Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study G. Sandrini, M. Färkkilä, G. Burgess, et al. Neurology 2002;59;1210-1217 DOI 10.1212/WNL.59.8.1210 This information
More informationValue of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
J Headache Pain (2006) 7:27 33 DOI 10.1007/s10194-006-0266-6 ORIGINAL Julio Pascual Hans-Christoph Diener Hélène Massiou Value of postmarketing surveillance studies in achieving a complete picture of antimigraine
More informationEvaluating the triptans
The American Journal of Medicine (2005) Vol 118, Suppl 1, 28S 35S Evaluating the triptans Ninan T. Mathew, MD, a Elizabeth W. Loder, MD b a From the Houston Headache Clinic, and Department of Neurology,
More informationANTIMIGRAINE MEDICINES
1 07.00.00.00 - ANTIMIGRAINE MEDICINES 1. Summary statement For acute migraine therapy the following new medicine is proposed: Sumatriptan 50 mg. 2. 3. Global Campaign to Reduce the Burden of Headache
More informationZolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study
is effective and well tolerated in Japanese patients with migraine: a dose response study F Sakai 1, M Iwata 2, K Tashiro 3, Y Itoyama 4, S Tsuji 5, Y Fukuuchi 6, G Sobue 7, K Nakashima 8 & M Morimatsu
More informationEarly treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan
Blackwell Science, LtdOxford, UKCHACephalalgia1468-2982Blackwell Science, 20042411925933Original ArticleEarly treatment of migraine with sumatriptanj Scholpp et al. Early treatment of a migraine attack
More informationmedications. This was an openlabel study consisting of patients with migraines who historically failed to respond to oral triptan
J Headache Pain (2007) 8:13 18 DOI 10.1007/s10194-007-0354-7 ORIGINAL Seymour Diamond Fred G. Freitag Alexander Feoktistov George Nissan Sumatriptan 6 mg subcutaneous as an effective migraine treatment
More informationTriptans: Nonresponse, Recurrence, and Serious AEs for Many Patients
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial,
More informationResearch Submission. ISSN doi: /head Published by Wiley Periodicals, Inc.
Headache 213 The Authors Headache published by Wiley Periodicals, Inc. on behalf of American Headache Society ISSN 17-8748 doi: 1.1111/head.12257 Published by Wiley Periodicals, Inc. Research Submission
More informationZolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice
J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred
More informationEditorial Team Conflict of Interest Statements
Editorial Team Conflict of Interest Statements Editor in Chief David Dodick Advisory board/consultant: Allergan, Amgen, Alder, Arteaus, Pfizer, Colucid, Merck, ENeura, NuPathe, Eli Lilly, Autonomic Technologies,
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationLasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine
(200 mg and 100 mg) Compared to for Acute Treatment of Migraine Bernice Kuca, M.S. 1 ; Linda A. Wietecha, B.S.N., M.S. 2 ; Paul H. Berg, M.S. 2 ; Sheena K. Aurora, M.D. 2 1 CoLucid Pharmaceuticals, Inc.,
More informationPer cent of patients with chronic migraine who responded per onabotulinumtoxina treatment cycle: PREEMPT
Migraine 1 Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA 2 Department of Neurology, Mayo Clinic Arizona, Phoenix, Arizona, USA 3 Department of Neurology and Neurological
More informationAcute migr REVIEW 6 PRACTICAL NEUROLOGY
6 PRACTICAL NEUROLOGY REVIEW Pract Neurol: first published as 10.1111/j.1474-7766.2004.03-205.x on 1 February 2004. Downloaded from http://pn.bmj.com/ Acute migr on 15 July 2018 by guest. Protected by
More informationThe use of combination therapies in the acute management of migraine
REVIEW The use of combination therapies in the acute management of migraine Abouch Valenty Krymchantowski Headache Center of Rio, Rio de Janeiro, Brazil; Outpatient Headache Unit of the Instituto de Neurologia
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationPatients preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine
J Headache Pain (2005) 6:112 120 DOI 10.1007/s10194-005-0164-3 REVIEW Andrew J. Dowson Stewart J. Tepper Carl Dahlöf Patients preference for triptans and other medications as a tool for assessing the efficacy
More informationCalcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine
The new england journal of medicine original article Calcitonin Gene Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine Jes Olesen, M.D., Hans-Christoph Diener, M.D.,
More informationStroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
More informationRizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial
J Headache Pain (2007) 8:175 179 DOI 10.1007/s10194-007-0386-7 ORIGINAL Usha Kant Misra Jayantee Kalita Rama Kant Yadav Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial Received:
More informationTreatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study
J Headache Pain (2005) 6:405 411 DOI 10.1007/s10194-005-0237-3 ORIGINAL Marek Gawel Jürgen Aschoff Arne May Bruce R. Charlesworth on behalf of the REALIZE Study Group Treatment satisfaction with zolmitriptan
More informationMigraine Diagnosis and Treatment: Results From the American Migraine Study II
Migraine Diagnosis and Treatment: Results From the American Migraine Study II Richard B. Lipton, MD; Seymour Diamond, MD; Michael Reed, PhD; Merle L. Diamond, MD; Walter F. Stewart, MPH, PhD Objective.
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29646 holds various files of this Leiden University dissertation. Author: Dekker, François (Frans) Title: Patients preference in migraine Issue Date: 2014-11-05
More informationPharmacological treatments for acute migraine: quantitative systematic review
Pain 97 (2002) 247 257 www.elsevier.com/locate/pain Pharmacological treatments for acute migraine: quantitative systematic review Anna D. Oldman, Lesley A. Smith, Henry J. McQuay, R. Andrew Moore* Pain
More informationTABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours
ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary
More informationDoes analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
DOI 10.1186/s40064-015-1386-8 RESEARCH Open Access Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse Fayyaz Ahmed *, Hassan
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationMEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache
MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended
More informationISSN doi: /head.13327
Headache VC 18 The Authors Headache: The Journal Head and Face Pain published by Wiley Periodicals, Inc. on behalf American Headache Society ISSN 17-8748 doi:.1111/head.13327 Research Submission Use Most
More informationAn Economic Evaluation of Triptan Products for Migraine
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR86647655Original ArticleEconomic Evaluation of TriptansPerfetto et al. Volume 8 Number 6 2005 VALUE IN HEALTH An Economic Evaluation
More informationCrossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine in Migraine
Original Paper Eur Neurol 2003;49:20 29 DOI: 10.1159/000067018 Received: March 13, 2002 Accepted: September 10, 2002 Crossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine
More informationAdult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationFinancial Support: This study was co-funded by OptiNose US, Inc., Yardley, PA, USA, and Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA.
Headache 2015 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals, Inc. on behalf of American Headache Society ISSN 0017-8748 doi: 10.1111/head.12583 Published by Wiley
More informationResearch Submission. ISSN doi: /head Published by Wiley Periodicals, Inc. Headache 2013 American Headache Society
Headache 2013 American Headache Society ISSN 0017-8748 doi: 10.1111/head.12150 Published by Wiley Periodicals, Inc. Research Submission Sex Differences in the Prevalence, Symptoms, and Associated Features
More informationTopiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders
J Headache Pain (2012) 13:53 59 DOI 10.1007/s10194-011-0395-4 ORIGINAL Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders Abouch Valenty Krymchantowski
More informationRizatriptan in the treatment of migraine
EXPERT OPINION Rizatriptan in the treatment of migraine Miguel JA Láinez Department of Neurology, University Clinic Hospital, University of Valencia, Valencia, Spain Correspondence: Miguel JA Láinez Department
More information...SELECTED ABSTRACTS...
The following abstracts, from medical journals containing literature on migraine management, were selected for their relevance to this Special Report supplement. Two Sumatriptan Studies Two double-blind
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 8/29/06 Triptans: almotriptan, Amerge, Axert, Frova,
More informationMigraineurs have specific preferences with regard to migraine therapy. In surveys,
Patient Treatment Preferences and the 5-HT 1B/1D Agonists Robert E. Ryan, Jr, MD REVIEW ARTICLE Migraineurs have specific preferences with regard to migraine therapy. In surveys, they consistently cite
More informationHans-Christoph Diener 1*, Morris Gold 2 and Martina Hagen 3
Diener et al. The Journal of Headache and Pain 2014, 15:76 RESEARCH ARTICLE Open Access Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone
More informationAspirin Is Efficacious for the Treatment of Acute Migraine
Research Submission Aspirin Is Efficacious for the Treatment of Acute Migraine Richard B. Lipton, MD; Jerome Goldstein, MD; Jeffrey S. Baggish, MD; Alberto R. Yataco, MD; James V. Sorrentino, PhD; John
More informationHarold G. Wolff Lecture Award Winner
Headache 2008 the Authors Journal compilation 2008 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2008.01217.x Published by Wiley Periodicals, Inc. Harold G. Wolff Lecture Award Winner
More informationDrug Class Review on Triptans
Drug Class Review on UPDATED FINAL REPORT #1 December 2003 Mark Helfand, MD, MPH Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Table of Contents Introduction
More informationISPUB.COM. C Suthisisang, N Poolsup, N Suksomboon INTRODUCTION
ISPUB.COM The Internet Journal of Pain, Symptom Control and Palliative Care Volume 8 Number 2 Efficacy And Safety Of Sumatriptan Plus Naproxen Sodium In The Acute Treatment Of Migraine: Systematic Review
More informationClinical Characteristics of Chronic Daily Headache Patients Visit to University Hospital
Clinical Characteristics of Chronic Daily Headache Patients Visit to University Hospital Jin-Kuk Do, M.D., Hee-Jong Oh, M.D., Dong-Kuck Lee, M.D. Department of Neurology, Taegu Hyosung Catholic University
More informationDrug Class Review on Triptans
Drug Class Review on Triptans Final Report Update 3 November 2005 Original Report Date: March 2003 Update 1 Report Date: December 2003 Update 2 Report Date: September 2004 A literature scan of this topic
More informationSetting The setting of the study was primary care. The economic study was conducted in the USA.
A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point Williams P, Reeder C E Record Status This is a
More informationSpecific Objectives A. Topics to be lectured and discussed at the plenary sessions
Specific Objectives A. Topics to be lectured and discussed at the plenary sessions 0. Introduction: Good morning ICHD-III! Let s start at the very beginning. When you read you begin with A-B-C, so when
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInpatient Treatment of Status Migraine With Dihydroergotamine in Children and Adolescents
Headache 2008 the Authors Journal compilation 2008 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2008.01293.x Published by Wiley Periodicals, Inc. Brief Communication Inpatient Treatment
More informationDrug Class Review on the Triptans
Drug Class Review on the Final Report March 7, 2003 Expires October 31, 2003 Mark Helfand, MD, MPH Kim Peterson, MS Produced by Oregon Health & Science University 3181 SW Sam Jackson Park Road Mailcode:
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli
The European Headache School 2012 ACUTE TREATMENT FOR MIGRAINE Cristina Tassorelli Headache Science Centre, IRCCS Neurological Institute C. Mondino Foundation - Pavia University Centre for Adaptive Disorders
More informationPharmacy Medical Necessity Guidelines: Migraine Medications
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationCost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine Williams P, Reeder C E
Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine Williams P, Reeder C E Record Status This is a critical abstract of an economic evaluation that meets the criteria for
More informationRichard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via
More informationARTICLE. Migraine Therapeutics in Adolescents. A Systematic Analysis and Historic Perspectives of Triptan Trials in Adolescents
COMPARATIVE EFFECTIVENESS RESEARCH ARTICLE Migraine Therapeutics in Adolescents A Systematic Analysis and Historic Perspectives of Triptan Trials in Adolescents Haihao Sun, MD, PhD; Eric Bastings, MD;
More informationThe prevalence of premonitory symptoms in migraine: a questionnaire study in 461 patients
Blackwell Publishing LtdOxford, UKCHACephalalgia0333-1024Blackwell Science, 20062006261012091213Original ArticleThe prevalence of premonitory symptoms in migrainegg Schoonman et al. The prevalence of premonitory
More informationA Prospective, Randomized Trial of Intravenous Prochlorperazine Versus Subcutaneous Sumatriptan in Acute Migraine Therapy in the Emergency Department
PAIN MANAGEMENT/ORIGINAL RESEARCH A Prospective, Randomized Trial of Intravenous Prochlorperazine Versus Subcutaneous Sumatriptan in Acute Migraine Therapy in the Emergency Department Mark A. Kostic, MD,
More informationMigraine Management. Roger Cady, MD Headache Care Center Springfield, MO
Migraine Management Roger Cady, MD Headache Care Center Springfield, MO Disclosures Objectives The evolution of migraine From benign episodic (benign) headache to potentially a devastating chronic disease
More informationORIGINAL CONTRIBUTION. Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain
ORIGINAL CONTRIBUTION Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain Three Double-blind, Randomized, -Controlled Trials Richard B. Lipton, MD; Walter
More informationAn economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D
An economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D Record Status This is a critical abstract of an economic evaluation that meets the
More informationPromius Pharma, a subsidiary of Dr. Reddy s Laboratories, Princeton, NJ; 2 Vedanta Research, Chapel Hill, NC; 3
Triptan Use and Discontinuation Among a Population Sample of Persons with Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study Aftab Alam, MBBS, MS, MBA 1 ; Sagar Munjal, MD 1
More informationComparison of dynamic (brush) and static (pressure) mechanical allodynia in migraine
Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology July 2006 Comparison of dynamic (brush) and static (pressure) mechanical allodynia in
More informationMigraine much more than just a headache
Migraine much more than just a headache Session hosted by Teva UK Limited PUU4 11:15 12:15 UK/NHSS/18/0021b Date of Preparation: August 2018 The views expressed in this presentation are those of the speaker
More informationMigraine Acute treatment
Migraine Acute treatment Elizabeth Loder, MD, MPH Professor of Neurology, Harvard Medical School Chief, Division of Headache, Department of Neurology, Brigham and Women s Hospital, Boston, MA Disclosures
More informationMigraine is a common and disabling illness, affecting
original Research Sumatriptan/Naproxen Sodium as Early Intervention for Migraine: Effects on Functional Ability, Productivity, and Satisfaction in 2 Randomized Controlled Trials Frederick R. Taylor, MD,
More informationONZETRA XSAIL (sumatriptan) nasal powder
ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationTriptan Therapy in Migraine
The new england journal of medicine clinical therapeutics Triptan Therapy in Migraine Elizabeth Loder, M.D., M.P.H. This Journal feature begins with a case vignette that includes a therapeutic recommendation.
More informationRISK FACTORS AND PROGNOSIS OF CHRONIC MIGRAINE
RISK FACTORS AND PROGNOSIS OF CHRONIC MIGRAINE Gretchen E. Tietjen, MD University of Toledo Toledo, Ohio Learning objectives At the conclusion of this presentation, participants should be able to: 1. Understand
More informationFaculty Disclosures. Learning Objectives. Acute Treatment Strategies
WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received
More informationCalcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value
Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value Background Draft Background and Scope December 4, 2017
More informationCombination Treatment for Menstrual Migraine and Dysmenorrhea Using Sumatriptan Naproxen Two Randomized Controlled Trials
Combination Treatment for Menstrual Migraine and Dysmenorrhea Using Sumatriptan Naproxen Two Randomized Controlled Trials Lisa K. Mannix, MD, Vincent T. Martin, MD, Roger K. Cady, MD, Merle L. Diamond,
More informationPrevalence of primary headaches in Germany: results of the German Headache Consortium Study
J Headache Pain (2012) 13:215 223 DOI 10.1007/s10194-012-0425-x ORIGINAL Prevalence of primary headaches in Germany: results of the German Headache Consortium Study M-S Yoon Z. Katsarava M. Obermann G.
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/29646 holds various files of this Leiden University dissertation. Author: Dekker, François (Frans) Title: Patients preference in migraine Issue Date: 2014-11-05
More informationAnti-Migraine Agents
DRUG POLICY BENEFIT APPLICATION Anti-Migraine Agents Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationUTILIZATION MANAGEMENT CRITERIA
SUMATRIPTAN (ALSUMA, IMITREX, SUMAVEL DOSEPRO, ZECUITY ) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: Serotonin 5-HT1 receptor agonists Imitrex (sumatriptan), Alsuma (sumatriptan),
More informationMigraine strikes study: factors in patients decision to treat early
J Headache Pain (2009) 10:93 99 DOI 10.1007/s10194-008-0091-1 ORIGINAL Migraine strikes study: factors in patients decision to treat early Wendy Golden Æ Judith K. Evans Æ Henry Hu Received: 17 October
More informationAndrew J. Dowson Hélène Massiou Sheena K. Aurora
J Headache Pain (2005) 6:81 87 DOI 10.1007/s10194-005-0156-3 ORIGINAL Andrew J. Dowson Hélène Massiou Sheena K. Aurora Managing migraine headaches experienced by patients who self-report with menstrually
More informationEffectiveness of Pharmacological Treatments in Imploding vs. Exploding Headaches
Effectiveness of Pharmacological Treatments in Imploding vs. Exploding Headaches Item Type Thesis Authors Hunt, Megan Publisher The University of Arizona. Rights Copyright is held by the author. Digital
More informationSUMAVEL DOSEPRO (sumatriptan succinate) solution for injection
SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationRelieving migraine pain: Sorting through the options
REVIEW LISA K., MD * Headache specialist, Cincinnati, Ohio Relieving migraine pain: Sorting through the options ABSTRACT Although triptans are a major advance in the treatment of migraine, the optimal
More informationARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract
Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines Brian Schuler, PharmD Candidate 2018 1 1 University of Findlay College of Pharmacy Abstract Migraines are the third most prevalent
More informationMIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.
MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am
More informationCase Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches
Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily
More informationAleksandra Radojičić. Headache Center, Neurology Clinic, Clinical Center of Serbia
European Headache School Belgrade 2012 MEDICATION OVERUSE HEADACHE Aleksandra Radojičić Headache Center, Neurology Clinic, Clinical Center of Serbia Historical data First cases were described in XVII century
More information5 HT receptor agonists (triptans) and Pediatric Migraine Critically Appraised Topic (CAT)
5 HT receptor agonists (triptans) and Pediatric Migraine Critically Appraised Topic (CAT) PICOT Question: In children and adolescents does use of 5 HT receptor agonists (triptans) versus no treatment treat
More informationA Cost-Effectiveness Analysis of Eletriptan 40 and 80 mg versus Sumatriptan 50 and 100 mg in the Acute Treatment of Migraine
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152003 ISPOJuly/August 200364438447Original ArticleCost-Effectiveness of Eletriptan versus SumatriptanWells et al. Volume 6 umber 4 2003 VALUE I
More informationSubmission for. Reclassification from
Submission for Reclassification from Prescription Medicine to Pharmacist Only Medicine Zomig (Zolmitriptan) AstraZeneca Limited PO Box 1301 Auckland January 2009 This document is protected by copyright
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationDefining the Differences Between Episodic Migraine and Chronic Migraine
Curr Pain Headache Rep (2012) 16:86 92 DOI 10.1007/s11916-011-0233-z CHRONIC DAILY HEADACHE (SJ WANG, SECTION EDITOR) Defining the Differences Between Episodic Migraine and Chronic Migraine Zaza Katsarava
More informationIs the Migraid device an asset in the non-pharmacologic treatment of migraine?
Acta neurol. belg., 2007, 107, 40-46 Is the Migraid device an asset in the non-pharmacologic treatment of migraine? Herman PIETERSE 1,3, Joop A. M. KUSTER 2 and Luc M. VAN BORTEL 1 1 Heymans Institute
More informationMigraine is defined as recurrent attacks of unilateral
JOURNAL OF CAFFEINE RESEARCH Volume 5, Number 3, 2015 ª Mary Ann Liebert, Inc. DOI: 10.1089/jcr.2015.0004 Intravenous Caffeine for the Treatment of Acute Migraine: APilotStudy Alireza Baratloo, MD, 1 Ahmed
More information